Differential properties of mibefradil hypertension and angina

Journal of Hypertension, Supplement

Volumn 15, Issue 5, 1997, Pages

  Kobrin, Isaac ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

Amlodipine; Anti anginal therapy; Antihypertensive therapy; Diltiazem; Mibefradil; Nifedipine

Indexed keywords

AMLODIPINE; CALCIUM ANTAGONIST; DILTIAZEM; GLYCERYL TRINITRATE; HYDROCHLOROTHIAZIDE; MIBEFRADIL; NIFEDIPINE; PLACEBO;

ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; ARTERIAL PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DEMOGRAPHY; DRUG ACTIVITY; DRUG SAFETY; DRUG TOLERANCE; DYSPEPSIA; FATIGUE; FLUSHING; GERIATRIC PATIENT; HEADACHE; HEART PALPITATION; HEART RATE; HIGH RISK PATIENT; HOLTER MONITORING; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LEG EDEMA; NAUSEA; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

ANGINA PECTORIS; BENZIMIDAZOLES; CALCIUM CHANNEL BLOCKERS; DILTIAZEM; DOUBLE-BLIND METHOD; HEART RATE; HUMANS; HYPERTENSION; MIBEFRADIL; NIFEDIPINE; TETRAHYDRONAPHTHALENES;

EID: 0031468192     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. 2+ channels by Ro 40-5967. Circ Res 1994, 75:144-148.
2. Bursztyn M, Kadr H, Tilvis R, et al.: Mibefradil, a novel calcium antagonist. In elderly hypertensives: favorable hemodynamics and pharmacokinetics. Am Heart J 1997, 134:238-247.
3. Bernink P, Prager G, Schelling A, Kobrin I: Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Hypertension 1996, 27:426-432.
4. Oparil S, Kobrin I, Abernethy D, Levine B, Reif M, Shepherd A: Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension. Am J Hypertens 1997, 10:735-742.
5. Carney S, Wing L, Ribeiro A, et al.: The addition of mibefradil to chronic hydrochlorothiazide therapy in hypertensive patients is associated with a significant antihypertensive effect. J Hum Hypertens 1997, 11:387-393.
6. Alpert J, Kobrin I, DeQuattro V, Friedman R, Shepherd A, Fenster P: Additional anti-anginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta-blocker for chronic stable angina pectoris. Am J Cardiol 1997, 79:1025-1030.
7. Bakx A, van der Wall E, Braun S, Emanuelsson H, Bruschke A, Kobrin I: Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Am Heart J 1995, 130:748-757.
8. Braun S, van der Wall E, Emanuelsson H, Kobrin I: Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. J Am Coll Cardiol 1996, 27:317-322.
9. Schneeweiss A, Kobrin I, Caspi A, et al.: Adding the new calcium antagonist mibefradil to patients on chronic beta-blocker therapy results in improved anti-anginal and anti-ischemic efficacy. Am Heart J 1997 (in press).
10. Tzivoni D, Kadr H, Braat S, Rutsch W, Ramires J, Kobrin I: Efficacy of mibefradil in comparison to amlodipine in suppressing exercise-induced and daily silent ischemia: results of a multicenter, placebo-controlled trial. Circulation 1997 (in press).
11. Massie B, Chrysant S, Jain A, Weir M, Weiss R, Kobrin I: Antihypertensive effects of mibefradil: a double-blind comparison with diltiazem CD. Clin Cardiol 1997, 20:562-568.
12. Viskoper R, Bernink P, Schelling A, et al.: A randomized, double-blind trial comparing mibefradil and amlodipine: two long-acting calcium antagonists with similar efficacy but different tolerability profiles. J Hum Hypertens 1997, 11:459-466.
13. Woittiez A, Huysmans F, Bailey R, et al.: A comparison of the safety and efficacy of mibefradil and nifedipine SR in patients with renal disease and hypertension. Clin Nephrol 1997 (in press).
14. Lacourcière Y, Poirer L, Lefebvre J, Archambault F, Dalle Ave S, Ward C: The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension. Am J Hypertens 1997, 10:189-196.
15. Davies G, Kobrin I, Caspi A, et al.: Long-term anti-anginal and anti-ischemic effects of mibefradil, the novel T-type calcium channel blocker: a multicenter, double-blind, placebo-controlled, randomized comparison with diltiazem SR. Am Heart J 1997 (in press).
16. Kannel W, Kannel C, Paffenbarger R, Cupples A: Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987, 113:1489-1494.
17. Gillum R, Makuc D, Feldman J: Pulse rate, coronary heart disease, and death: the NHAHES I epidemiologic follow-up study. Am Heart J 1991, 121:172-177.
18. Perski A, Ollson G, Landou C, de Faire U, Theorell T, Hamsten A: Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J 1992, 123:609-616.
19. Palatini P, Julius S: Heart rate and the cardiovascular risk. J Hypertens 1997, 15:3-17.
20. Pepine C, Cohn P, Deedwania P, et al.: Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life: the Atenolol Silent Ischemia Study (ASIST). Circulation 1994, 90:762-768.
21. Rousseau M, Hayashida W, van Eyll C, et al.: Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocker, mibefradil, in patients with varying degrees of left ventricular systolic dysfunction. J Am Coll Cardiol 1996, 28:972-979.
22. Véniant M, Clozel J-P, Hess P, Wolfgang R: Ro 40-5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction. J Cardiovasc Pharmacol 1991, 17:277-284.
23. Su J, Renaud N, Carayon A, Crozatier B, Hittinger L: Effects of the calcium channel blockers, diltiazem and Ro 40-5967, on systemic haemodynamics and plasma noradrenaline levels in conscious dogs with pacing-induced heart failure. Br J Pharmacol 1994, 13:395-402.
24. 3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther 1990, 4:731-736.
25. Levine T: The design of the Mortality Assessment in Congestive Heart Failure trial (MACH-1, mibefradii). Clin Cardiol 1997, 20:320-326.